Analysis: Biotech Buys Seen in Cancer, Immunology, Neurology

As large drug makers continue to cut back internal research and development programs, pharma looks to acquire biotechs with significant revenue potential. Biogen Idec is named among the particularly attractive takeover candidates with its robust drug development pipeline, which includes Dexpramipexole for ALS.

Click here to read more.

Share this: